Abstract 1179P
Background
There is a paucity of real-world evidence addressing mesenchymal-epithelial transition exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC). Incidence is 3–4% for all histological subtypes. Recently, METex14 has emerged as a target lesion sensitive to MET inhibitors (METi) in advanced NSCLC, with overall response rates varying between 3–46%. Furthermore, some studies suggest improved sensitivity to immune checkpoint inhibitors (ICIs). However, the role of METex14 in clinical routine treatment remains unclear.
Methods
We retrospectively collected clinical data of NSCLC patients of all clinical stages with METex14 mutations treated at two Swedish University Hospitals, Karolinska University Hospital and Skåne University Hospital, between 2014–2022.
Results
We screened a total of 62 patients, of which 51 met the inclusion criteria. The majority of patients had adenocarcinoma (74.5%). Furthermore, there were 11 patients (21.6%) with stage I, 5 patients (9.8%) with stage II, 7 patients (13.7%) with stage III, and 28 patients (54.9%) with stage IV disease. High programmed death-ligand 1 status (PD-L1≥50%) was present in 21 patients (45.1%) and 15 patients (29.4%) received ICIs. Kaplan-Meier estimates of median overall survival (mOS) with corresponding 95% confidence intervals (95% CI) was 17.0 months (95% CI, 9.8–24.2) for the intention-to-treat population (N = 51). In addition, patients who received METi (N = 13) vs. those without METi (N = 38) had a mOS of 19.0 months (95% CI, 9.4–28.6) and 16.0 months (95% CI, 7.1–24.9; p = 0.52), respectively. The mOS for patients who received ICIs (N = 15) was 15.0 months (95% CI, 11.7–18.3) vs. those without (N = 36) was 21.0 months (95% CI, 7.8–34.2; p = 0.97).
Conclusions
There is a lack of real-world evidence of NSCLC patients with METex14 of all clinical stages. Based on our results, the mOS advantage of METi is limited and ICIs do not appear to improve mOS. However, although not statistically significant results due to the low number of events, a longer follow-up is necessary. Nevertheless, suitable therapy remains to be an unmet clinical need for this patient subgroup.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.